Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Smith & Nephew agreed to sell a U.K. plant that makes wound management products to SWM’s DelStar Medical subsidiary for an undisclosed amount.
The plant in Gilberdyke, England, makes polyurethane films for Smith & Nephew and nets and foams used in wound dressings by other manufacturers. Smith & Nephew plans to relocate the polyurethane film operation to an existing plant in Hull, while the net and foam manufacturing will be absorbed into DelStar. Read more
Boston Scientific said today that its next-generation Synergy stent, featuring a bioabsorbable polymer impregnated with everolimus, is the 1st such device to pass a U.S. pivotal trial.
The 1,684-patient Evolve II trial, comparing Synergy with Boston Scientific’s Promus drug-eluting stent, featured patients with “both clinical and angiographic complexity to a degree not observed in prior U.S. pivotal trials for DES,” Boston Scientific said. Read more
Hologic said it fired its chief admin officer, Mark Casey, who also served and general counsel and secretary, effective Dec. 19.
The Bedford, Mass.-based women’s health company said Casey agreed to resign at its request but did not elaborate on the reasons for the ouster. Read more